Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Optimistic Outlook on Larimar Therapeutics’ Nomlabofusp: Advancements in Clinical Trials for Adolescents with Friedreich’s Ataxia
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track ...
USA Today29d
What to know about nervous system disease 'ataxia'
In such cases, an inability to balance is a symptom known as ataxia. But ataxia can also be its own condition or disease. As a stand-alone condition, "ataxia is a degenerative disease of the ...
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...
Solid Biosciences' Ataxia Treatment Receives FDA Fast-Track Designation
Fast-track status will allow Solid Biosciences to have more frequent meetings with the FDA throughout the treatment-development process and, potentially, get the product to patients faster than would ...
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the ...
Seeking Alpha23d
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better
Nomlabofusp For The Treatment Of Patients With Friedreich's Ataxia As I stated above, the company released positive initial data from the long-term open-label extension [OLE] study, using ...
Pharmabiz2d
Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia
Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia: Bala Cynwyd, Pennsylvania Saturday, January 25, 2025, 15: ...
H.C. Wainwright maintains $30 target on Voyager Therapeutics stock
The confidence in Voyager Therapeutics (NASDAQ:VYGR)' stock is further supported by the company's strategic collaborations, ...